Oral Oncolytics Will Require Health Care System to Adapt
Judging from the drug pipeline, the future of oncology is oral chemotherapy.
Judging from the drug pipeline, the future of oncology is oral chemotherapy.
The European Commission has approved enzalutamide as monotherapy and in combination with ADT in BCR nonmetastatic hormone-sensitive prostate cancer.
Michael Wang, MD, presents the primary analysis results from the multinational, randomized, double-blind, phase 3 SYMPATICO study comparing ibrutinib plus venetoclax vs ibrutinib plus placebo…
Amy DeZern, MD, MHS, discusses a retrospective study on healthcare claims for patients with MDS treated with luspatercept and reviews patient-reported outcomes from the COMMANDS…
The 15 inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice.
Leland Metheny, MD, discusses ongoing clinical trials and their implications for the field of hematologic oncology.
Erin Frances Cobain, MD, discusses unanswered questions regarding the use of ribociclib and immunotherapy in early-stage breast cancer.
Kian-Huat Lim, MD, PhD, discusses the role of multidisciplinary collaboration and clinical trials in the treatment of pancreatic cancer.
The 15 inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice.
Changchun Deng, MD, PhD, discusses factors to consider when sequencing covalent BTK inhibitors and venetoclax in patients with CLL/SLL.
The 15 inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice.